Octave wins grant to develop blood test for measuring MS progression
Funding from Valhalla Foundation will advance objective disease assessment by Andrea Lobo, PhD | October 10, 2025 A new grant from the Valhalla Foundation will…
video: Moderated & Public Q&A with MS Neurologists Boster and LaGanke
Event date: July 26, 2025 Moderator: Stuart Schlossman, President of MS Views and News / MS Patient Advocate At the…
Stuart Schlossman
Two-Year CHIMES Study Data Highlight Effect of Ocrelizumab in Diverse Relapsing MS Patient Population
Key Takeaways New findings reveal ocrelizumab significantly improves symptoms, cognition, and fatigue in Black and Hispanic patients with relapsing multiple…
Stuart Schlossman
“The Immune System and MS Forum” – EASY Learning
Watch and Listen as MS Neurologists, Ben Thrower, MD and Aaron Boster, MD accurately and easily describe Multiple Sclerosis and…
Stuart Schlossman
What to Do When Cold Weather Worsens MS Symptoms
Cold weather aggravates fatigue and spasticity for some with MS, but that doesn’t mean you have to hibernate all winter.…
Stuart Schlossman
How to Spot the Signs of an MS Flare
When new multiple sclerosis symptoms crop up or old ones worsen, you may be having an MS relapse. By Chris…
Stuart Schlossman
What to Expect From an MS Relapse
What can you expect from a Multiple Sclerosis relapse? Let’s take a look at one young Black woman’s personal journey…
Stuart Schlossman
What is a Multiple Sclerosis Pseudo-exacerbation?
Click the video box to watch this very well presented program Visit our MS Learning Channel on YouTube: http://www.youtube.com/msviewsandnews…
Stuart Schlossman
MS Relapse: 6 Things to Do During a Flare-Up
Multiple sclerosis (MS) can be unpredictable. About 85 percent of people with MS are diagnosed with relapsing-remitting MS (RRMS), which is characterized…
Stuart Schlossman
Alemtuzumab outcomes by age: Post hoc analysis from the randomized CARE-MS studies over 8 years
Abstract Background: Alemtuzumab significantly improved clinical and MRI outcomes vs. subcutaneous interferon beta-1a (SC IFNB-1a) in the CARE-MS trials (NCT00530348, NCT00548405),…
Stuart Schlossman
